Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy
NCT ID: NCT01736020
Last Updated: 2016-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
293 participants
INTERVENTIONAL
2009-09-30
2017-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)
NCT03375294
Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD)
NCT00749203
Ketamine-enhanced Prolonged Exposure Therapy in PTSD
NCT04560660
Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)
NCT01477762
Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)
NCT02397889
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Dexmedetomidine
A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Propofol
A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Ketamine
A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Nitrous Oxide
A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Placebo
Placebo
Dexmedetomidine
Dexmedetomidine intravenous infusion during scan.
Dexmedetomidine
A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Propofol
Propofol intravenous infusion during scan.
Propofol
A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Ketamine
Ketamine intravenous infusion during scan.
Ketamine
A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Nitrous Oxide
Nitrous Oxide inhalation during scan.
Nitrous Oxide
A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Propofol
A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Ketamine
A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Nitrous Oxide
A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Between the ages of 18 and 35.
Exclusion Criteria
* Left-handed.
* Unusual facial anatomy.
* History of esophageal reflux.
* Respiratory problems.
* Central nervous system disorders.
* Cardiovascular problems.
* Kidney disease.
* Diabetes.
* History of Substance abuse.
* History of adverse anesthetic reactions.
* Hepatitis.
* Failure to pass MRI screening questionnaire.
* Fear of small-enclosed spaces.
* Mental illness.
* Non-native English speakers.
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
University of California, Irvine
OTHER
Southern California Institute for Research and Education
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Alkire
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael T Alkire, MD
Role: PRINCIPAL_INVESTIGATOR
University of California, Irvine and Long Beach VA Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California, Irvine
Irvine, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MIRB 1007, UCI 2004-3707
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.